Advertisement

Regional origin and decrease of pain in patients with depressive symptoms under treatment with venlafaxine

  • Stefan BegréEmail author
  • Martin Traber
  • Martin Gerber
  • Roland von Känel
Original Paper

Abstract

Objective

Patient’s language, tradition, conventions, and customs may all determine integration into a society and are also part of the doctor–patient relationship that influences diagnostic and therapeutic outcome. Language barrier and sociocultural disparity of Eastern and Southern European patients may hamper recovery from pain and depression compared to Middle European patients in Switzerland.

Methods

In a prospective naturalistic observational trial we investigated the influence of regional origin on treatment outcome in 420 pain sufferers with depressive symptoms from all over Switzerland who were treated with venlafaxine by 122 physicians in primary care. Physicians rated severity of depressive symptoms using the clinical global impression severity scale and pain intensity by means of visual analogue scales. We hypothesized that in Eastern and Southern European patients the magnitude of pain reduction under treatment with venlafaxine is less compared to Middle European patients.

Results

Three months after study entry, Middle European patients were found to profit more from treatment with venlafaxine in terms of severity of depression and pain intensity than patients from Eastern Europe and Southern Europe.

Conclusion

Regional origin may contribute to the magnitude of pain reduction in patients with depressive symptoms under treatment with venlafaxine. Our results provide a rational for care provider educational programs aimed at improving capacities in treating patients from different regional origin with psychosomatic complaints such as depression and comorbid pain.

Keywords

Pain Depression Clinical practice Migration Switzerland 

Notes

Acknowledgment

We are grateful to Wyeth Pharmaceuticals AG, Switzerland for providing its data pool to perform this study.

Reference List

  1. 1.
    Adelman LC, Adelman JU, Von Seggern R, Mannix LK (2000) Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 40:572–580CrossRefPubMedGoogle Scholar
  2. 2.
    Arnow BA, Hunkeler EM, Blasey CM, Lee J, Constantino MJ, Fireman B, Kraemer HC, Dea R, Robinson R, Hayward C (2006) Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 68:262–268CrossRefPubMedGoogle Scholar
  3. 3.
    Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K (2004) Impact of pain on depression treatment response in primary care. Psychosom Med 66:17–22CrossRefPubMedGoogle Scholar
  4. 4.
    Bair MJ, Robinson RL, Katon W, Kroenke K (2003) Depression and pain comorbidity: a literature review. Arch Intern Med 163:2433–2445CrossRefPubMedGoogle Scholar
  5. 5.
    Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ (2006) What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67:1428–1434CrossRefPubMedGoogle Scholar
  6. 6.
    Bates MS, Edwards WT, Anderson KO (1993) Ethnocultural influences on variation in chronic pain perception. Pain 52:101–112CrossRefPubMedGoogle Scholar
  7. 7.
    Begré S, Traber M, Gerber M, von Kaenel R (2008) Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: an observational study in primary care. Eur Psychiatry 23(3):178–186CrossRefPubMedGoogle Scholar
  8. 8.
    Cutrona CE, Russell DW, Brown PA, Clark LA, Hessling RM, Gardner KA (2005) Neighborhood context, personality, and stressful life events as predictors of depression among African American women. J Abnorm Psychol 114:3–15CrossRefPubMedGoogle Scholar
  9. 9.
    Eisenman DP, Gelberg L, Liu H, Shapiro MF (2003) Mental health and health-related quality of life among adult Latino primary care patients living in the United States with previous exposure to political violence. JAMA 290:627–634CrossRefPubMedGoogle Scholar
  10. 10.
    Fillingim RB (2005) Individual differences in pain responses. Curr Rheumatol Rep 7:342–347CrossRefPubMedGoogle Scholar
  11. 11.
    Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV (2001) Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 98:737–744CrossRefPubMedGoogle Scholar
  12. 12.
    Geerlings SW, Twisk JW, Beekman AT, Deeg DJ, van Tilburg W (2002) Longitudinal relationship between pain and depression in older adults: sex, age and physical disability. Soc Psychiatry Psychiatr Epidemiol 37:23–30CrossRefPubMedGoogle Scholar
  13. 13.
    Gilgen D, Gross CS, Maeusezahl D, Frey C, Tanner M, Weiss MG, Hatz C (2002) Impact of organized violence on illness experience of Turkish/Kurdish and Bosnian migrant patients in primary care. J Travel Med 9:236–240PubMedGoogle Scholar
  14. 14.
    Greenberg PE, Leong SA, Birnbaum HG, Robinson RL (2003) The economic burden of depression with painful symptoms. J Clin Psychiatry 64(Suppl 7):17–23PubMedGoogle Scholar
  15. 15.
    Guy W (1976) ECDEU assessment manual for psychopharmacology (rev edn). National Institute for Mental Health, RockvilleGoogle Scholar
  16. 16.
    Karp JF (2004) Venlafaxine XR and chronic pelvic pain syndrome. J Clin Psychiatry 65:880–881PubMedCrossRefGoogle Scholar
  17. 17.
    Leyer EM (1990) Hidden interpersonal structures in medical and psychotherapy interaction with foreign patients—presented and discussed with the example of a Turkish patient with chronic pain. Psychother Psychosom Med Psychol 40:423–431PubMedGoogle Scholar
  18. 18.
    Lin EH, Katon WJ, Simon GE, Von Korff M, Bush TM, Walker EA, Unutzer J, Ludman EJ (2000) Low-intensity treatment of depression in primary care: is it problematic? Gen Hosp Psychiatry 22:78–83CrossRefPubMedGoogle Scholar
  19. 19.
    Lynch ME (2001) Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 26:30–36PubMedGoogle Scholar
  20. 20.
    Mbaya P (2002) Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol 17:335–339CrossRefPubMedGoogle Scholar
  21. 21.
    McCrae JD, Lumley MA (1998) Health status in sickle cell disease: examining the roles of pain coping strategies, somatic awareness, and negative affectivity. J Behav Med 21:35–55CrossRefPubMedGoogle Scholar
  22. 22.
    Reuben SS (2005) The prevention of post-surgical neuralgia. Pain 113:242–243CrossRefPubMedGoogle Scholar
  23. 23.
    Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998) A randomized, placebo-controlled, dose–response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116–122PubMedGoogle Scholar
  24. 24.
    Sabbioni ME, Eugster S (2001) Interactions of a history of migration with the course of pain disorder. J Psychosom Res 50:267–269CrossRefPubMedGoogle Scholar
  25. 25.
    Sayar K, Aksu G, Ak I, Tosun M (2003) Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37:1561–1565CrossRefPubMedGoogle Scholar
  26. 26.
    Schouten BC, Meeuwesen L (2006) Cultural differences in medical communication: a review of the literature. Patient Educ Couns 64:21–34CrossRefPubMedGoogle Scholar
  27. 27.
    Songer DA, Schulte H (1996) Venlafaxine for the treatment of chronic pain. Am J Psychiatry 153:737PubMedGoogle Scholar
  28. 28.
    Ulusahin A, Basoglu M, Paykel ES (1994) A cross-cultural comparative study of depressive symptoms in British and Turkish clinical samples. Soc Psychiatry Psychiatr Epidemiol 29:31–39PubMedGoogle Scholar
  29. 29.
    Weilburg JB, O’Leary KM, Meigs JB, Hennen J, Stafford RS (2003) Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatr Serv 54:1233–1239CrossRefPubMedGoogle Scholar
  30. 30.
    Williams LS, Jones WJ, Shen J, Robinson RL, Kroenke K (2004) Outcomes of newly referred neurology outpatients with depression and pain. Neurology 63:674–677PubMedGoogle Scholar
  31. 31.
    Yucel A, Ozyalcin S, Koknel TG, Kiziltan E, Yucel B, Andersen OK, Arendt-Nielsen L, Disci R (2005) The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 9:407–416CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Stefan Begré
    • 1
    Email author
  • Martin Traber
    • 2
  • Martin Gerber
    • 3
  • Roland von Känel
    • 1
  1. 1.Division of Psychosomatic Medicine, Department of General Internal MedicineUniversity Hospital/InselspitalBernSwitzerland
  2. 2.Wyeth Pharmaceuticals AGZugSwitzerland
  3. 3.GEM Clinical Research Consulting M. GerberUnterägeri/ZGSwitzerland

Personalised recommendations